10-Q Filing

TEVA PHARMACEUTICAL INDUSTRIES LTD CIK: 818686 Q1 2022

Filing Information

Form Type	10-Q
Accession Number	`0001193125-22-138669`
Period End Date	20220331
Filing Date	20220503
Fiscal Year	2022
Fiscal Period	Q1
XBRL Instance	d312501d10q_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 87 Income Statement 44 Cash Flow Statement 63 Stockholders Equity 15 Comprehensive Income 14

Balance Sheet 87 line items

Line Item	Tag	Value	Unit	Period
Allowance for credit losses	`AllowanceForDoubtfulAccountsReceivableCurrent`	$90.00M	USD	Point-in-time
Allowance for credit losses	`AllowanceForDoubtfulAccountsReceivableCurrent`	$91.00M	USD	Point-in-time
Common stock, par or stated value per share	`CommonStockParOrStatedValuePerShare`	0.10	CHF	Point-in-time
Common stock, par or stated value per share	`CommonStockParOrStatedValuePerShare`	0.10	CHF	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.17B	USD	Point-in-time
Ordinary shares, authorized	`CommonStockSharesAuthorized`	2.50B	shares	Point-in-time
Ordinary shares, authorized	`CommonStockSharesAuthorized`	2.50B	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.17B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.74B	USD	Point-in-time
Accounts receivables, net of allowance for credit losses of $91 million and $90 million as of March 31, 2022 and December 31, 2021	`AccountsReceivableNetCurrent`	$4.53B	USD	Point-in-time
Accounts receivables, net of allowance for credit losses of $91 million and $90 million as of March 31, 2022 and December 31, 2021	`AccountsReceivableNetCurrent`	$4.25B	USD	Point-in-time
Ordinary shares, issued	`CommonStockSharesIssued`	1.21B	shares	Point-in-time
Ordinary shares, issued	`CommonStockSharesIssued`	1.22B	shares	Point-in-time
Inventories	`InventoryNet`	$4.01B	USD	Point-in-time
Treasury shares	`TreasuryStockShares`	106.00M	shares	Point-in-time
Inventories	`InventoryNet`	$3.82B	USD	Point-in-time
Treasury shares	`TreasuryStockShares`	106.00M	shares	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$1.06B	USD	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$1.07B	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$933.00M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$965.00M	USD	Point-in-time
Assets held for sale	`AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$13.00M	USD	Point-in-time
Assets held for sale	`AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$19.00M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$12.57B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$12.45B	USD	Point-in-time
Deferred income taxes	`DeferredIncomeTaxAssetsNet`	$596.00M	USD	Point-in-time
Deferred income taxes	`DeferredIncomeTaxAssetsNet`	$637.00M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$515.00M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$472.00M	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$5.93B	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$5.98B	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$495.00M	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$464.00M	USD	Point-in-time
Identifiable intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$7.47B	USD	Point-in-time
Identifiable intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$7.12B	USD	Point-in-time
Goodwill	`Goodwill`	$19.99B	USD	Point-in-time
Goodwill	`Goodwill`	$20.04B	USD	Point-in-time
Total assets	`Assets`	$47.06B	USD	Point-in-time
Total assets	`Assets`	$47.67B	USD	Point-in-time
Short-term debt	`DebtCurrent`	$2.08B	USD	Point-in-time
Short-term debt	`DebtCurrent`	$1.43B	USD	Point-in-time
Sales reserves and allowances	`SalesReservesAndAllowances`	$4.24B	USD	Point-in-time
Sales reserves and allowances	`SalesReservesAndAllowances`	$3.81B	USD	Point-in-time
Accounts payables	`AccountsPayableTradeCurrent`	$1.69B	USD	Point-in-time
Accounts payables	`AccountsPayableTradeCurrent`	$1.75B	USD	Point-in-time
Employee-related obligations	`EmployeeRelatedLiabilitiesCurrent`	$563.00M	USD	Point-in-time
Employee-related obligations	`EmployeeRelatedLiabilitiesCurrent`	$481.00M	USD	Point-in-time
Accrued expenses	`AccruedExpenses`	$2.21B	USD	Point-in-time
Accrued expenses	`AccruedExpenses`	$2.60B	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$903.00M	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$900.00M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$11.61B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$11.03B	USD	Point-in-time
Deferred income taxes	`DeferredTaxAndOtherLiabilitiesNoncurrent`	$784.00M	USD	Point-in-time
Deferred income taxes	`DeferredTaxAndOtherLiabilitiesNoncurrent`	$666.00M	USD	Point-in-time
Other taxes and long-term liabilities	`OtherLiabilitiesNoncurrent`	$3.29B	USD	Point-in-time
Other taxes and long-term liabilities	`OtherLiabilitiesNoncurrent`	$2.58B	USD	Point-in-time
Senior notes and loans	`LongTermNotesAndLoans`	$20.84B	USD	Point-in-time
Senior notes and loans	`LongTermNotesAndLoans`	$21.62B	USD	Point-in-time
Operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$416.00M	USD	Point-in-time
Operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$393.00M	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$25.19B	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$25.39B	USD	Point-in-time
Commitments and contingencies, see note 10	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies, see note 10	`CommitmentsAndContingencies`	-	USD	Point-in-time
Total liabilities	`Liabilities`	$36.80B	USD	Point-in-time
Total liabilities	`Liabilities`	$36.42B	USD	Point-in-time
Ordinary shares of NIS 0.10 par value per share; March 31, 2022 and December 31, 2021: authorized 2,495 million shares; issued 1,216 million shares and 1,209 million shares, respectively.	`CommonStockValue`	$57.00M	USD	Point-in-time
Ordinary shares of NIS 0.10 par value per share; March 31, 2022 and December 31, 2021: authorized 2,495 million shares; issued 1,216 million shares and 1,209 million shares, respectively.	`CommonStockValue`	$57.00M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$27.59B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$27.56B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-10.53B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-11.48B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-2.69B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-2.68B	USD	Point-in-time
Treasury shares as of March 31, 2022 and December 31, 2021: 106 million ordinary shares	`TreasuryStockValue`	$4.13B	USD	Point-in-time
Treasury shares as of March 31, 2022 and December 31, 2021: 106 million ordinary shares	`TreasuryStockValue`	$4.13B	USD	Point-in-time
Stockholders' equity attributable to Teva shareholders	`StockholdersEquity`	$9.34B	USD	Point-in-time
Stockholders' equity attributable to Teva shareholders	`StockholdersEquity`	$10.28B	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	$966.00M	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	$916.00M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$10.97B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$10.26B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.06B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.24B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$47.06B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$47.67B	USD	Point-in-time

Income Statement 44 line items

Line Item	Tag	Value	Unit	Period
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$3.66B	USD	1 Quarter
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$3.98B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$2.10B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$1.92B	USD	1 Quarter
Gross profit	`GrossProfit`	$1.74B	USD	1 Quarter
Gross profit	`GrossProfit`	$1.88B	USD	1 Quarter
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$254.00M	USD	1 Quarter
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$225.00M	USD	1 Quarter
Selling and marketing expenses	`SellingAndMarketingExpense`	$585.00M	USD	1 Quarter
Selling and marketing expenses	`SellingAndMarketingExpense`	$584.00M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$290.00M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$296.00M	USD	1 Quarter
Intangible assets impairments	`IntangibleAssetsImpairments`	$149.00M	USD	1 Quarter
Intangible assets impairments	`IntangibleAssetsImpairments`	$79.00M	USD	1 Quarter
Other asset impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$128.00M	USD	1 Quarter
Other asset impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$137.00M	USD	1 Quarter
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$1.12B	USD	1 Quarter
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$104.00M	USD	1 Quarter
Other income	`OtherOperatingIncomeExpenseNet`	$52.00M	USD	1 Quarter
Other income	`OtherOperatingIncomeExpenseNet`	$5.00M	USD	1 Quarter
Operating income (loss)	`OperatingIncomeLoss`	$-713.00M	USD	1 Quarter
Operating income (loss)	`OperatingIncomeLoss`	$434.00M	USD	1 Quarter
Financial expenses, net	`NonoperatingIncomeExpense`	$-258.00M	USD	1 Quarter
Financial expenses, net	`NonoperatingIncomeExpense`	$-290.00M	USD	1 Quarter
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-971.00M	USD	1 Quarter
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$144.00M	USD	1 Quarter
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	$2.00M	USD	1 Quarter
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	$62.00M	USD	1 Quarter
Share in (profits) losses of associated companies, net	`IncomeLossFromEquityMethodInvestments`	$3.00M	USD	1 Quarter
Share in (profits) losses of associated companies, net	`IncomeLossFromEquityMethodInvestments`	$21.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$84.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-952.00M	USD	1 Quarter
Net income (loss) attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$7.00M	USD	1 Quarter
Net income (loss) attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$3.00M	USD	1 Quarter
Net income (loss) attributable to Teva	`NetIncomeLoss`	$77.00M	USD	1 Quarter
Net income (loss) attributable to Teva	`NetIncomeLoss`	$-955.00M	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$0.07	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$-0.86	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$-0.86	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$0.07	USD	1 Quarter
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.11B	shares	1 Quarter
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.10B	shares	1 Quarter
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.11B	shares	1 Quarter
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.11B	shares	1 Quarter

Cash Flow Statement 63 line items

Line Item	Tag	Value	Unit	Period
Net income (loss)	`ProfitLoss`	$84.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-952.00M	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$323.00M	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$376.00M	USD	1 Quarter
Impairment of long-lived assets and assets held for sale	`AssetImpairmentCharges`	$127.00M	USD	1 Quarter
Impairment of long-lived assets and assets held for sale	`AssetImpairmentCharges`	$165.00M	USD	1 Quarter
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$-559.00M	USD	1 Quarter
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$1.08B	USD	1 Quarter
Deferred income taxes net and uncertain tax positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$-175.00M	USD	1 Quarter
Deferred income taxes net and uncertain tax positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$-11.00M	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$24.00M	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$31.00M	USD	1 Quarter
Other items	`OtherOperatingActivitiesCashFlowStatement`	$-10.00M	USD	1 Quarter
Other items	`OtherOperatingActivitiesCashFlowStatement`	$30.00M	USD	1 Quarter
Net loss (gain) from investments and from sale of long lived assets	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$-74.00M	USD	1 Quarter
Net loss (gain) from investments and from sale of long lived assets	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$23.00M	USD	1 Quarter
Net cash provided by (used in) operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-405.00M	USD	1 Quarter
Net cash provided by (used in) operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-49.00M	USD	1 Quarter
Beneficial interest collected in exchange for securitized trade receivables	`ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables`	$476.00M	USD	1 Quarter
Beneficial interest collected in exchange for securitized trade receivables	`ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables`	$305.00M	USD	1 Quarter
Proceeds from sale of business and long lived assets	`ProceedsFromDivestitureOfBusinesses`	$138.00M	USD	1 Quarter
Proceeds from sale of business and long lived assets	`ProceedsFromDivestitureOfBusinesses`	$25.00M	USD	1 Quarter
Acquisition of businesses, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	-	USD	1 Quarter
Acquisition of businesses, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$7.00M	USD	1 Quarter
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$157.00M	USD	1 Quarter
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$150.00M	USD	1 Quarter
Purchases of investments and other assets	`PaymentToAcquireMarketableSecuritiesAndOtherAssets`	$2.00M	USD	1 Quarter
Purchases of investments and other assets	`PaymentToAcquireMarketableSecuritiesAndOtherAssets`	$4.00M	USD	1 Quarter
Proceeds from sale of investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	-	USD	1 Quarter
Proceeds from sale of investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$46.00M	USD	1 Quarter
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	$1.00M	USD	1 Quarter
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	-	USD	1 Quarter
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$161.00M	USD	1 Quarter
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$508.00M	USD	1 Quarter
Redemption of convertible senior notes	`DebtConversionConvertedInstrumentAmount1`	$491.00M	USD	1 Quarter
Redemption of convertible senior notes	`DebtConversionConvertedInstrumentAmount1`	-	USD	1 Quarter
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	$2.00M	USD	1 Quarter
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	$-2.00M	USD	1 Quarter
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$2.00M	USD	1 Quarter
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-493.00M	USD	1 Quarter
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-44.00M	USD	1 Quarter
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-62.00M	USD	1 Quarter
Net change in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-434.00M	USD	1 Quarter
Net change in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$52.00M	USD	1 Quarter
Balance of cash, cash equivalents and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.25B	USD	Point-in-time
Balance of cash, cash equivalents and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.18B	USD	Point-in-time
Balance of cash, cash equivalents and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.74B	USD	Point-in-time
Balance of cash, cash equivalents and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.20B	USD	Point-in-time
Balance of cash, cash equivalents and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.25B	USD	Point-in-time
Balance of cash, cash equivalents and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.18B	USD	Point-in-time
Balance of cash, cash equivalents and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.74B	USD	Point-in-time
Balance of cash, cash equivalents and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.20B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.17B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.17B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.74B	USD	Point-in-time
Restricted cash included in other current assets	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$75.00M	USD	Point-in-time
Restricted cash included in other current assets	`RestrictedCashAndCashEquivalentsAtCarryingValue`	-	USD	Point-in-time
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.25B	USD	Point-in-time
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.18B	USD	Point-in-time
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.74B	USD	Point-in-time
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.20B	USD	Point-in-time
Beneficial interest obtained in exchange for securitized accounts receivables	`BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables`	$488.00M	USD	Point-in-time
Beneficial interest obtained in exchange for securitized accounts receivables	`BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables`	$299.00M	USD	Point-in-time

Stockholders Equity 15 line items

Line Item	Tag	Value	Unit	Period
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$10.97B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$10.26B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.06B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.24B	USD	Point-in-time
Net Income (loss)	`ProfitLoss`	$84.00M	USD	1 Quarter
Net Income (loss)	`ProfitLoss`	$-952.00M	USD	1 Quarter
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-57.00M	USD	1 Quarter
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-201.00M	USD	1 Quarter
Issuance of Shares, value	`StockIssuedDuringPeriodValueNewIssues`	$1.00M	USD	1 Quarter
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$24.00M	USD	1 Quarter
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$31.00M	USD	1 Quarter
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$10.97B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$10.26B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.06B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.24B	USD	Point-in-time

Comprehensive Income 14 line items

Line Item	Tag	Value	Unit	Period
Net income (loss)	`ProfitLoss`	$84.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-952.00M	USD	1 Quarter
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-208.00M	USD	1 Quarter
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-64.00M	USD	1 Quarter
Unrealized gain (loss) from derivative financial instruments, net	`UnrealizedGainLossOnDerivativeNetOfTax`	$7.00M	USD	1 Quarter
Unrealized gain (loss) from derivative financial instruments, net	`UnrealizedGainLossOnDerivativeNetOfTax`	$7.00M	USD	1 Quarter
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-57.00M	USD	1 Quarter
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-201.00M	USD	1 Quarter
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-117.00M	USD	1 Quarter
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-1.01B	USD	1 Quarter
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-60.00M	USD	1 Quarter
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-50.00M	USD	1 Quarter
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTax`	$-57.00M	USD	1 Quarter
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTax`	$-959.00M	USD	1 Quarter

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.